| DRUG | PREGNANCY CONSIDERATIONS | USE | POST-NATAL/BREAST FEEDING |
| Inteferon-β | Only limited data exist on the drug’s effect on the fetus. No increased incidence of miscarriages, Congenital malformation, or SGA (Small for gestational age) | Use is contra-indicated in pregnancy (Patients are usually advised to stop use after conception) | Use not advised with breast feeding |
| Glatiramer Acetate | Limited data. No evidence of increased frequency of miscarriages, congenital malformations, or SGA | Use contraindicated in pregnancy (Patients are usually advised to stop use after conception) | May use with caution during breast feeding |
| Corticosteroids (Prednisone, Prednisolone) | First trimester use has been associated with fetal orofacial clefts. May cause Gestational diabetes, Hypertension. Heavy doses over a long period may cause FGR (Intrauterine fetal growth restriction)/SGA | Use with appropriate surveillance | May use during breast feeding. Breast feeding advised 4 hours post administration to reduce infant exposure. |
| Natalizumab | Limited data. Not known to increase the incidence of miscarriages, or congenital malformation. Crosses placenta (particularly in the 3rd trimester), has been associated with SGA and fetal haematological abnormalities (anaemia, thrombocytopenia) | May be used as a 2nd line agent in challenging cases with appropriate surveillance | Use not advised with breast feeding |
| Immunosuppressive Agents-Methotrexate Cyclophosphamide Myclofentolate Mitoxantrone | Teratogenic. Stop usage at least 6 months before pregnancy. Ensure appropriate contraception during usage | Contra-indicated | Contra-indicated |